10-Q: Cocrystal Pharma Reports Q2 2026 Results, Faces Going Concern Doubt

Cocrystal Pharma, Inc. reported its second quarter 2026 financial results, highlighting ongoing research and development efforts but also substantial net losses and a critical need for future financing.

Summary

• Cocrystal Pharma, Inc. reported its financial results for the quarter and six months ended June 30, 2026.
• The company experienced a net loss of $3.164 million for the three months ended June 30, 2026, and $5.463 million for the six months ended June 30, 2026.
• Research and development expenses increased significantly due to clinical trial costs for CDI-988.
• As of June 30, 2026, the company had $2.169 million in unrestricted cash.
• A substantial doubt about the company's ability to continue as a going concern was noted by management and the independent auditor.
• On July 31, 2026, the company raised $5.0 million in gross proceeds through a Securities Purchase Agreement with OPKO Health, Inc.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's continued net losses, substantial cash burn, and the substantial doubt about its ability to continue as a going concern, despite a recent capital raise.

Positives

• Received a $5.0 million gross capital raise on July 31, 2026, from OPKO Health, Inc.
• Continued progress in research and development, particularly with norovirus and coronavirus candidate CDI-988, which received FDA Fast Track designation.
• Favorable safety and tolerability results reported for CDI-988 Phase 1 studies.
• Initiated Phase 1b challenge study for CDI-988 as a norovirus preventive and treatment in February 2026.
• Demonstrated pan-viral activity of direct-acting antivirals against multiple viruses, including hantavirus and influenza.
• CC-42344 showed potential efficacy against the new Texas avian flu strain in in vitro studies.
• Government contract revenue of $105,000 and $330,000 recognized for the three and six months ended June 30, 2026, respectively.

Negatives

• Reported a net loss of $3.164 million for the three months ended June 30, 2026, and $5.463 million for the six months ended June 30, 2026.
• Cash and restricted cash decreased to $2.244 million as of June 30, 2026, from $7.100 million at the beginning of the period.
• The company has substantial accumulated deficits and has incurred net losses and negative operating cash flows since inception.
• Management and the independent auditor have expressed substantial doubt about the company's ability to continue as a going concern.
• The Phase 2a study for oral CC-42344 in the UK yielded no scientifically viable results due to unexpectedly low influenza infection rates.
• A dispute has arisen with the UK clinical research organization (CRO) regarding the CC-42344 study, with the company seeking a refund or a redo of the study.
• The company expects to continue incurring substantial operating losses and negative cash flows from operations over the next several years.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to ongoing net losses and negative cash flows.
• The company's current resources are not sufficient to fund operations beyond the next 12 months.
• Failure to secure additional funding could lead to delays, reductions, or elimination of clinical trials or research and development programs.
• The Influenza A program faces significant risks and uncertainties following the initial Phase 2a study that failed to yield scientifically viable results.
• A dispute with a UK CRO regarding the CC-42344 study could result in financial or operational setbacks.
• The company's products require regulatory approvals (e.g., FDA) which may be delayed, denied, or difficult to maintain.
• Competition from currently available treatments, therapies, and larger companies poses a risk to market penetration and success.

Future Outlook

The company expects to continue incurring substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases. Future cash requirements will depend on factors including economic conditions, product development progress, clinical trial outcomes, regulatory approvals, patent protection, competitive landscape, financing availability, market development, and legal proceedings. The company intends to fund future operations through additional private or public equity offerings and strategic partnerships.

Management Comments

• The Company's activities since inception have principally consisted of acquiring product and technology rights, raising capital, and performing research and development.
• Successful completion of the Company's development programs, obtaining regulatory approvals of its products and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to access potential markets, secure financing, develop a customer base, attract, retain and motivate qualified personnel, and develop strategic alliances.
• We believe that our current resources will not be sufficient to fund our operations beyond the next 12 months.
• We have historically not generated sustained positive cash flow and if we are not able to secure additional funding when needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical trials or research and development programs.
• If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its drug development activities.
• The Company expects to continue incurring substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases.

Industry Context

StockSavvy.ai notes that Cocrystal Pharma operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on antiviral drug development. The company's challenges in securing consistent funding and the long development timelines for new drugs are common industry-wide issues. The recent capital raise, while positive, is a short-term solution to ongoing liquidity concerns typical for clinical-stage biotechs.

Comparison to Industry Standards

• The company's net loss of $5.463 million for the first six months of 2026 and its cash burn rate are within the expected range for a clinical-stage biopharmaceutical company investing heavily in R&D.
• However, the substantial doubt about its going concern status, despite a recent $5 million capital raise, indicates a more precarious financial position compared to many peers who may have stronger balance sheets or more advanced-stage products.
• The FDA's Fast Track designation for CDI-988 is a positive step, aligning with industry trends of seeking accelerated pathways for promising treatments for serious conditions.
• The dispute with the UK CRO regarding the CC-42344 study highlights the operational and contractual risks inherent in clinical trial management, a common challenge across the industry.

Legal Proceedings

• A dispute has arisen with the United Kingdom clinical research organization (CRO) that performed the Phase 2a study for CC-42344. The Company contends the CRO breached its agreement and is seeking a refund or redo of the study. The CRO denies liability and seeks additional payment. The Company has initiated arbitration.

Related Party Transactions

• The lessor of the Miami, Florida lease is a limited liability company controlled by Dr. Phillip Frost, a director and principal stockholder of the Company. Lease payments and related expenses were $32,000 for the six months ended June 30, 2026.
• On July 31, 2026, the Company sold 5,474,053 shares of common stock to OPKO Health, Inc. for $5.0 million. Dr. Phillip Frost is Chairman and CEO of OPKO Health, Inc., and is also a co-founder, director, and principal stockholder of Cocrystal Pharma, Inc.

Stakeholder Impact

• Shareholders may experience dilution due to ongoing capital raises and the company's continued need for funding.
• Employees may face uncertainty due to the company's going concern issues and potential curtailment of R&D programs.
• Creditors and suppliers may face risks related to the company's ability to meet its financial obligations.
• The company's ability to attract and retain qualified personnel could be impacted by its financial situation and going concern status.

Next Steps

• Continue advancing preclinical and clinical drug candidate programs with proceeds from the recent capital raise.
• Continue evaluating CDI-988 for additional program development.
• Evaluate in vitro antiviral activity against the Andes hantavirus replication enzyme.
• Subject to resolution of the CRO dispute or raising capital, continue development of oral CC-42344 as a treatment for pandemic and seasonal influenza A.
• Seek a partner for further clinical development of CC-31244 for Hepatitis C.
• Continue to pursue development of novel antiviral compounds for the treatment of coronavirus infections.

Key Dates

Recommendation

The company's continued substantial net losses, significant cash burn, and the explicit statement of substantial doubt about its ability to continue as a going concern, despite a recent capital raise, present significant risks. The setbacks in the influenza program and the ongoing dispute with the CRO further add to the uncertainty. While there is potential in the antiviral pipeline, the immediate financial precariousness and operational challenges suggest a sell recommendation for risk-averse investors.

Keywords

antiviral, drug development, clinical stage, norovirus, influenza, coronavirus, CDI-988, CC-42344